GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$48.65
-0.48 (-0.98%)
As of Mar 24, 9:57 PM ET ·
Financial Highlights (FY 2026)
Revenue
279.70M
Net Income
-4,514,140,048
Gross Margin
44.5%
Profit Margin
-1,613.9%
Rev Growth
+104.8%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 44.5% 65.8% 65.8% 65.8%
Operating Margin -1,743.0% 10.1% 9.2% 8.6%
Profit Margin -1,613.9% 8.0% 7.6% 7.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 279.70M 2.03B 2.02B 1.78B
Gross Profit 124.41M 1.34B 1.33B 1.17B
Operating Income -4,875,263,503 204.57M 184.76M 152.85M
Net Income -4,514,140,048 163.05M 154.03M 135.92M
Gross Margin 44.5% 65.8% 65.8% 65.8%
Operating Margin -1,743.0% 10.1% 9.2% 8.6%
Profit Margin -1,613.9% 8.0% 7.6% 7.7%
Rev Growth +104.8% +17.3% +15.5% +5.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 1.55B 1.78B 1.62B
Total Equity 1.84B 1.86B 2.14B
D/E Ratio 0.84 0.96 0.76
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,576,935,899 233.27M 214.07M 192.49M
Free Cash Flow 175.18M 137.52M 156.47M